These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24061864)

  • 41. Serial-measured versus estimated creatinine clearance in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy.
    Chang GC; Yang TY; Shih CM; Lin LY; Lee HS; Chiang CD
    J Formos Med Assoc; 2003 Apr; 102(4):257-61. PubMed ID: 12833190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetics of the novel anticancer agent KRN7000.
    Crul M; Mathôt RA; Giaccone G; Punt CA; Rosing H; Hillebrand MX; Ando Y; Nishi N; Tanaka H; Schellens JM; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):287-93. PubMed ID: 11914907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Therapeutic efficacy and pharmacokinetics of cisplatin in patients with non-small cell lung cancer].
    Fukuoka M; Kitajima K; Takada M; Negoro M; Matsui S; Kusunoki K; Ryu Y; Sakai S; Takifuji N; KimuraT
    Nihon Kyobu Shikkan Gakkai Zasshi; 1987 Jan; 25(1):44-9. PubMed ID: 3037144
    [No Abstract]   [Full Text] [Related]  

  • 45. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
    Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
    Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
    Nalda-Molina R; Valenzuela B; Ramon-Lopez A; Miguel-Lillo B; Soto-Matos A; Perez-Ruixo JJ
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):97-108. PubMed ID: 18941750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.
    Hurkmans DP; Basak EA; van Dijk T; Mercieca D; Schreurs MWJ; Wijkhuijs AJM; Bins S; Hoop EO; Debets R; Joerger M; Odink A; van der Veldt AAM; van der Leest CH; Aerts JGJV; Mathijssen RHJ; Koolen SLW
    J Immunother Cancer; 2019 Jul; 7(1):192. PubMed ID: 31324223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhaled Cisplatin for NSCLC: Facts and Results.
    Kosmidis C; Sapalidis K; Zarogoulidis P; Sardeli C; Koulouris C; Giannakidis D; Pavlidis E; Katsaounis A; Michalopoulos N; Mantalobas S; Koimtzis G; Alexandrou V; Tsiouda T; Amaniti A; Kesisoglou I
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
    Freyer G; Tranchand B; Ligneau B; Ardiet C; Souquet PJ; Court-Fortune I; Riou R; Rebattu P; Boissel JP; Trillet-Lenoir V; Girard P
    Br J Clin Pharmacol; 2000 Oct; 50(4):315-24. PubMed ID: 11012554
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer.
    Bastian G; Barrail A; Urien S
    Anticancer Drugs; 2003 Nov; 14(10):817-24. PubMed ID: 14597876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of ertapenem in burns patients.
    Dailly E; Arnould JF; Fraissinet F; Naux E; Letard de la Bouralière MA; Bouquié R; Deslandes G; Jolliet P; Le Floch R
    Int J Antimicrob Agents; 2013 Jul; 42(1):48-52. PubMed ID: 23578794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cisplatin pharmacokinetics in elderly patients.
    Bonetti A; Franceschi T; Apostoli P; Cetto GL; Recaldin E; Molino A; Leone R
    Ther Drug Monit; 1994 Oct; 16(5):477-82. PubMed ID: 7846745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.
    Pujol JL; Cupissol D; Gestin-Boyer C; Bres J; Serrou B; Michel FB
    Cancer Chemother Pharmacol; 1990; 27(1):72-5. PubMed ID: 2173980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.
    Hanada K; Nishijima K; Ogata H; Atagi S; Kawahara M
    Jpn J Clin Oncol; 2001 May; 31(5):179-84. PubMed ID: 11450990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.
    Launay-Iliadis MC; Bruno R; Cosson V; Vergniol JC; Oulid-Aissa D; Marty M; Clavel M; Aapro M; Le Bail N; Iliadis A
    Cancer Chemother Pharmacol; 1995; 37(1-2):47-54. PubMed ID: 7497596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Emoto-Yamamoto Y; Iida S; Kawanishi T; Fukuoka M
    J Clin Pharm Ther; 2015 Apr; 40(2):232-9. PubMed ID: 25402940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis.
    de Rouw N; Croes S; Posthuma R; Agterhuis DE; Schoenmaekers JJAO; Derijks HJ; Burger DM; Dingemans AM; Ter Heine R
    Lung Cancer; 2019 Apr; 130():156-158. PubMed ID: 30885337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preliminary Study on J-Resolved NMR Method Usability for Toxic Kidney's Injury Assessment.
    Doskocz M; Marchewka Z; Jeż M; Passowicz-Muszyńska E; Długosz A
    Adv Clin Exp Med; 2015; 24(4):629-35. PubMed ID: 26469107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM.
    Vermes A; Math t RA; van der Sijs IH; Dankert J; Guchelaar HJ
    Ther Drug Monit; 2000 Dec; 22(6):676-87. PubMed ID: 11128235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.